Literature DB >> 684152

Monitoring digoxin therapy. The use of plasma digoxin concentration measurements in the diagnosis of digoxin toxicity.

J K Aronson, D G Grahame-Smith, F M Wigley.   

Abstract

The usefulness of measuring plasma digoxin concentrations in the diagnosis of digoxin toxicity has been assessed in 83 in-patients. The mean plasma digoxin concentration in clinically toxic patients was significantly higher than the mean concentration in non-toxic patients. The overlap between the groups, however, was extensive and could partly be accounted for by hypokalaemia in those toxic patients whose plasma digoxin concentration was less than 3 ng/ml. There was, in addition, a higher incidence of hyperkalaemia, without obvious cause, in toxic patients than in non-toxic patients. Consideration of the incidence of various non-cardiac factors, specifically plasma potassium concentration greater than 5.0 mmol/l, plasma creatinine concentration greater than 150 mumol/l, daily maintenance dose greater than 6 microgram/kg, and age greater than 60 years, led to the development of guidelines to aid in the diagnosis of digoxin toxicity. Patients with plasma digoxin concentration greater than 3 ng/ml or with hypokalaemia should be considered probably toxic and those with plasma digoxin concentration greater than or equal to 3 ng/ml in the absence of hypokalaemia should only be considered toxic if they have at least two of the non-cardiac factors outlined above. Plasma digoxin concentrations could not be predicted with more than 31 per cent certainty by considering the magnitude of those non-cardiac factors.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 684152

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  16 in total

1.  The value of therapeutic drug monitoring to the practising physician--an hypothesis in need of testing.

Authors:  G T McInnes
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

2.  Correlation between manifestations of digoxin toxicity and serum digoxin, calcium, potassium, and magnesium concentrations and arterial pH.

Authors:  M Sonnenblick; A S Abraham; Z Meshulam; U Eylath
Journal:  Br Med J (Clin Res Ed)       Date:  1983-04-02

Review 3.  Clinical pharmacokinetics of cardiac glycosides in patients with renal dysfunction.

Authors:  J K Aronson
Journal:  Clin Pharmacokinet       Date:  1983 Mar-Apr       Impact factor: 6.447

Review 4.  Indications for the measurement of plasma digoxin concentrations.

Authors:  J K Aronson
Journal:  Drugs       Date:  1983-09       Impact factor: 9.546

Review 5.  Clinical pharmacokinetics of digoxin 1980.

Authors:  J K Aronson
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

6.  Digitalis: its place in modern therapy.

Authors:  A J Taggart; D G McDevitt
Journal:  Drugs       Date:  1980-11       Impact factor: 9.546

7.  The acute changes seen in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients during the early phases of digoxin therapy are not found during chronic therapy: pharmacological and therapeutic implications for chronic digoxin therapy.

Authors:  A R Ford; J K Aronson; D G Grahame-Smith; J G Carver
Journal:  Br J Clin Pharmacol       Date:  1979-08       Impact factor: 4.335

8.  Magnesium status and digoxin toxicity.

Authors:  I S Young; E M Goh; U H McKillop; C F Stanford; D P Nicholls; E R Trimble
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

Review 9.  Digoxin toxicity in the aged. Characterising and avoiding the problem.

Authors:  A P Passmore; G D Johnston
Journal:  Drugs Aging       Date:  1991 Sep-Oct       Impact factor: 3.923

Review 10.  Interpretation of drug levels in acute and chronic disease states.

Authors:  E Perucca; R Grimaldi; A Crema
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.